2024 ASCO® Annual Meeting Insights Hub
Meeting coverage & Vumedi’s exclusive highlights, all in one place.
Playback speed
10 seconds
ASCO® 2024 Insights: "RELATIVITY-047 Trial 3-Year OS and MSS Outcomes - Nivo + Rela vs. Nivo for Previously Untreated Metastatic/Unresectable Melanoma"
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Hussein Tawbi
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Hussein Tawbi
385 views
June 12, 2024
Chapters
RELATIVITY-047 Trial Overview & Design
00:00
3-Year Survival & Response Rates
02:56
Safety Profile & Future Directions
08:32
Login to view comments.
Click here to Login